A class of drugs for imaging of Alzheimer's disease progression and response to therapy. These radioactive compounds have the very unique and unprecedented ability to bind very specifically and irreversibly to butyrylcholinesterase (BChE). In addition to use as a highly efficient imaging model, there is the potential for therapeutic benefit due to the fact that the compounds inhibit BChE. An additional therapeutic use may stem from the fact that BChE is also expressed in ovarian cancer making the compounds useful in this area as well.
Alzheimer's disease is the most common cause of dementia, afflicting 24 million people worldwide. Despite of advances in medicine, currently there is no efficient imaging and treatment systems for Alzheimer's Disease. The technology presented is developed on growing demand for Alzheimer's Disease diagnostic and treatment tools among aging U.S. and Europe population.
Features & Benefits
US Patent Application Filed:
UNeMed Corporation offers a variety of licensing options and collaborative development opportunities with University of Nebraska Medical Center.
Technology Marketing and Licensing for The University of Nebraska Medical CenterView profile
Clients in focus...